Tag: NICE Guidance

Depression in adults: treatment and management

~ TRFT Library & Knowledge Service ~ Leave a comment

National Institute for Health and Care Excellence | Depression in adults: treatment and management | NICE guideline [NG222]

This guideline covers identifying, treating and managing depression in people aged 18 and over. It recommends treatments for first episodes of depression and further-line treatments, and provides advice on preventing relapse, and managing chronic depression, psychotic depression and depression with a coexisting diagnosis of personality disorder.

This guideline updates and replaces NICE guideline CG90 (October 2009). This guideline was previously called depression in adults: recognition and management.

Full detail: Depression in adults: treatment and management

NICE have also created a series of visual summaries to explain the treatment and management of depression in adults:

Thousands of people in England could benefit after NICE recommends treatment option for two forms of sight loss

~ TRFT Library & Knowledge Service ~ Leave a comment

NICE recommends faricimab as treatment option for adults with wet age-related macular degeneration or diabetic macular oedema | National Institute for Health and Care Excellence

Thousands of people in England could benefit after NICE published final draft guidance recommending a new drug to help treat two leading causes of sight loss and visual impairment. Clinical evidence shows faricimab (Vabysmo, Roche) is effective in improving vision or reducing vision loss and can be administered less frequently than other medicines currently available.

Faricimab is administered as an eye injection and is being recommended as an option for treating some adults with wet age-related macular degeneration (AMD) or with diabetic macular oedema (DMO).

In the key clinical trials, aflibercept, another eye injection drug used to treat AMD and DMO, was administered every 8 weeks, while faricimab dosing, based on assessments of the disease activity, allowed for an interval of up to 16 weeks between doses, and was found to be equally effective.

Up to 300,000 people in England with wet age-related macular degeneration (AMD) could be eligible to receive faricimab as part of their treatment alongside just over 28,000 people with diabetic macular oedema.

The final guidance is due to be published on June 29.

Full detail: Thousands of people in England could benefit after NICE recommends treatment option for two forms of sight loss

NICE recommends inducing women in labour earlier in new draft guidance

~ TRFT Library & Knowledge Service ~ Leave a comment

NICE | May 2021 | NICE recommends inducing women in labour earlier in new draft guidance

New draft guidance from NICE recommends pregnant women should be induced at 41 weeks and the induction should take place as soon as possible. The draft  recommends that women with uncomplicated singleton pregnancies should be offered induction at 41 weeks and the induction should take place as soon as possible. Previous guidelines advised induction between 41 and 42 weeks, and that women who had chosen not to be induced should be monitored after 42 weeks. If women choose not to have induced labour their decision should be supported and their care options discussed with them (Source: NICE).

The consultation is open until 6 July 2020

The guidance is expected to be published on 14 October 2021

Consultation documents available from NICE

NICE [press release] NICE recommends inducing women in labour earlier in new draft guidance

NICE COVID-19 rapid guideline: acute myocardial injury #covid19rftlks

~ TRFT Library & Knowledge Service ~ Leave a comment

NICE |  April 2020 | COVID-19 rapid guideline: acute myocardial injury

NICE has produced a rapid guideline  to help healthcare professionals who are not cardiology specialists identify and treat acute myocardial injury and its cardiac complications in adults with known or suspected COVID-19 but without known pre-existing cardiovascular disease.

nice.org.uk
Image source: nice.org.uk

To see the full size image of this 1 page summary visit NICE: 1-page summary of the recommendations on diagnosis and management 

The guideline covers care in a hospital setting. The recommendations are specifically for acute myocardial injury associated with COVID-19 and should be used alongside good clinical practice.

The recommendations bring together:

  • evidence from published literature on COVID-19 with acute myocardial injury
  • existing national and international guidance and policies
  • advice from specialists working in the NHS from across the UK. These include people with expertise and experience of treating patients with acute myocardial injury during the current COVID-19 pandemic (Source: NICE)